M
ild to moderate therapeutic hypothermia (32°C-33°C) has been used in clinical practice in pediatric patients with severe traumatic brain injury (TBI), specifically as a second-tier therapy (1, 2) . Two recent studies, including a multicenter trial, have demonstrated safety of this treatment modality after TBI in children, along with beneficial effects on intracranial hypertension (3, 4) . Neuroprotective effects of hypothermia have been shown in a variety of animal species and mechanisms of injury (5) (6) (7) (8) (9) , and clinical trials have reported efficacy in both cardiac arrest in adults (10, 11) and perinatal asphyxia in newborns (12) . Several secondary injury mechanisms are favorably influenced by moderate hypothermia in experimental TBI (13) (14) (15) . However, the precise mode of neuroprotective action of mild-moderate hypothermia is not known.
Moderate hypothermia has been shown to have beneficial effects on oxidative stress in experimental models of TBI. Generation of hydroxyl radicals as analyzed by salicylate-trapping method was attenuated by moderate hypothermia after fluid percussion injury in rats (16) . Furthermore, treatment of rats with moderate hypothermia after controlled cortical impact increased superoxide dismutase activity relative to values in injured normothermic animals (13) . Similarly, therapeutic hypothermia has been shown to attenuate consumption of endogenous antioxidants and decrease lipid peroxidation in experimental temporary focal ischemia and cardiac arrest (14, 15) .
Assessment of the extent of oxidative stress in vivo is a complex task requiring usage of a battery of assays evaluating radical scavenging capacity and oxidation products of biomolecules. We previously presented evidence for free radicalmediated lipid peroxidation (by assessment of F2-isoprostanes) and protein oxidation (by assessment of protein thiol) and sustained decreases in total antioxidant reserve and glutathione concentrations in cerebrospinal fluid (CSF) after severe TBI in infants and children. F2-isoprostanes are bioactive cyclopentanone prostaglandin-like compounds produced in vivo by free radical peroxidation of arachidonyl-containing lipids and represent a reliable lipid biomarker of oxidative stress (17) . Free radical attack on proteins results in oxidation of their sulfhydryl groups, leading to decreased protein thiol concentrations. Our findings suggested that these CSF markers could be valuable to assess the effect of therapies on oxidative stress after TBI in patients.
Several studies suggest that CSF oxidation markers might be associated with outcome after TBI. Pilitsis et al (16) demonstrated that elevated levels of highly oxidizable polyunsaturated fatty acids in CSF were associated with worse outcome in adults with severe TBI. Enhanced lipid peroxidation, as assessed by CSF thiobarbituric acid reactive substances, was reported to correlate with the severity of head injury in adults with contusion (18) . In a recent study, Darwish et al (19) showed that poor neurologic outcome was associated with increased levels of nitrotyrosine, a marker of protein damage by oxidative/nitrative stress, in CSF after TBI in adults. These studies indicate that CSF markers of oxidative stress may be useful in prognostication after TBI.
To date, there has not been any study assessing the effects of hypothermia on oxidative stress after clinical TBI in either adults or children. Therefore, in this study, we tested the hypothesis that therapeutic hypothermia attenuates oxidative damage as assessed by markers of lipid peroxidation, protein oxidation, and antioxidant status (reduced glutathione and total antioxidant reserve) in CSF after severe TBI in infants and children.
METHODS

Patient Selection and Data Collection.
We examined the effect of moderate therapeutic hypothermia on oxidative stress in CSF from subsets of patients (n ϭ 28) enrolled at our center in two concurrent randomized controlled trials assessing the effect and safety of moderate therapeutic hypothermia in severe TBI (Glasgow Coma Scale ͓GCS͔ score Յ8) in infants and children. The general paradigm for patients treated with hypothermia involved cooling to 32°C-33°C (within either 6 or 24 hours after injury) for 48 hours and then gradual rewarming. The details of the study protocols and results of these trials on clinical outcome have been previously reported (3) . Briefly, once the patient was randomized to normothermia or hypothermia, a temperature control unit with a rectal probe was used for surface cooling or warming as needed. Temperature was maintained by means of a rectal probe at 32°C-33°C for hypothermia and at 36.5°C-37.5°C for normothermia for the 48-hour study period. To prevent shivering, which could make cooling difficult, sedation and paralysis were used before the initiation of cooling (hypothermia group) and during the study period in both groups. Patients randomized to normothermia were maintained at 36.5°C-37.5°C throughout the study period and were passively warmed if their initial presenting core temperature was less than 36°C. After 48 hours of cooling, rewarming occurred by passively warming the patient 1°C every 3-4 hours so as to reach normothermia (36.5°C) within 12-18 hours (3). The predetermined entry criteria, in addition to closed head injury and a GCS score of Յ8, were age of 0 -156 months (multicenter trial) or 0Ϫ18 years (single center trial). Patients were excluded from the study if they had a normal initial computed tomography scan (no blood, fracture, swelling, and/or shift), GCS score of 8 with a computed tomography scan with only minimal abnormal findings, prolonged hypotension (Ͼ15 minutes) defined as a mean blood pressure less than fifth percentile for age, failure to obtain informed consent within 6 hours of injury (multicenter trial), failure to obtain informed consent within 24 hours of admission to Children's Hospital of Pittsburgh (single-center trial), brain dead clinically, penetrating cerebral injury, coagulopathy, prothrombin time Ͼ16 and partial thromboplastin time Ͼ40, or pregnancy. This study was approved by the Institutional Review Board of the Children's Hospital of Pittsburgh, and informed consent was obtained from parents for sample collection. CSF samples (n ϭ 76) were centrifuged for 10 minutes at 5000 ϫ g and stored at Ϫ70°C until the time of analysis. Demographic and clinical parameters are seen in Table 1 .
All patients with severe TBI admitted to the Children's Hospital of Pittsburgh were treated with ventricular catheter insertion, and CSF was drained continuously. All patients were also intubated and mechanically ventilated to PaCO 2 of 35-38 mm Hg. They received sedation with narcotics (fentanyl) and neuromuscular blockade with vecuronium bromide to maintain their intracranial pressure and cerebral perfusion pressure in the age-appropriate target range in accordance with the guidelines for management of severe pediatric TBI (1). Barbiturates and mechanical ventilation to PaCO 2 Ͻ35 mm Hg were used as second-tier therapies as needed for refractory intracranial hypertension.
Chemiluminescence Measurements of Total Antioxidant Reserve. Total antioxidant reserve in CSF was assayed by chemiluminescence produced in the presence of luminol and a source of peroxyl radicals, as described by Tyurina and co-workers (20) . A water-soluble azo-initiator, 2,2Ј-azobis(2-amidinopropane)dihydrochloride (AAPH), was used to produce peroxyl radicals at a constant rate. Oxidation of luminol (400 M) by AAPHderived peroxyl radicals was assayed by monitoring the chemiluminescence response. The reaction was initiated by addition of AAPH. A delay in the chemiluminescence response, which is caused by interaction of endogenous antioxidants with AAPH-derived peroxyl radicals, was observed on addition of CSF. On the basis of the known rate of peroxyl radical generation by AAPH, the amount of peroxyl radicals scavenged by endogenous antioxidants was determined. A Microlite ML 1000 microtiter plate luminometer (Dynatech Labs, Chantilly, VA) was used for these determinations.
Fluorescence Assay of Protein Sulfhydryls and Glutathione. CSF protein sulfhydryls (prot-SH) and glutathione concentrations were measured by fluorescent assay using ThioGlo-1 (Convalent Associates, Woburn, MA), a maleimide reagent that produces a highly fluorescent product on its reaction with sulfhydryl groups, as described previously (21) . A Cytofluor 2350 fluorescence plate reader (Millipore Corporation, Marlborough, MA) was used to detect fluorescence using excitation and emission wavelengths of 388 and 500 nm, respectively. The data acquired were exported from the spectrophotometer using Cytofluor software.
Determination of F2-Isoprostane (8-epiprostaglandin F2␣)
. CSF F2-isoprostane content was measured by a commercial enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI) with a detection limit: 2 pg/mL. Statistical Analysis. Data are shown as mean Ϯ standard error of mean. Demographic and clinical data were compared by Student's t test. The association between GCS score, age, gender, treatment (randomization to hypothermia or normothermia), time after injury, and CSF F2-isoprostane, prot-SH, glutathione, antioxidant reserve levels were assessed by bivariate and multiple regression models. Because there are multiple observations per person, standard regression models violated the assumption of independence of observations. Therefore, generalized estimating equation models, regression models that control for the correlation within individuals, were used. Some of the study patients randomized to therapeutic hypothermia did not reach the target temperature at the time of CSF sampling. Similarly, some patients randomized to normothermia were hypothermic at admission. To assess the impact of actual core temperature on CSF F2-isoprostane level, we used a second model that included the actual core temperature at the time of CSF sampling instead of randomization to hypothermia or normothermia. In each of the models, the beta-coefficient represents the average increase or decrease in CSF biochemical marker levels for a one-unit increase in continuous variables (e.g., temperature) or the difference in the average CSF biochemical marker level between the two groups for dichotomous variables.
RESULTS
Patient Demographics. Demographic and clinical parameters of TBI patients are shown in Table 1 . Age ranged from 2 months to 16 years. There were 13 patients randomized to hypothermia and 15 patients randomized to normothermia. Initial GCS score ranged between 3 and 8. Mechanism of injury included both accidental injury and child abuse. Five patients randomized to hypothermia and eight patients randomized to normothermia received barbiturates. One patient randomized to hypothermia and two patients randomized to normothermia underwent decrompressive craniotomy. There was no statistically significant difference between the groups for demographic and clinical characteristics.
Total Antioxidant Reserve. For all biochemical analysis, mean sample collection times were not different between hy- (Fig. 1) . Fig. 1) . There was an inverse relationship between temperature and CSF total antioxidant reserve after injury (p ϭ 0.022) ( Table 3) .
Glutathione. Glutathione levels progressively decreased after the peak on day 1, similar to that previously reported (Fig. 2) . Bivariate and multiple regression models revealed a tendency for higher glutathione levels in CSF with hypothermia (p ϭ 0.097 and p ϭ 0.090) ( Table 2 ). There was an inverse relationship between temperature and glutathione concentration in CSF after injury (p ϭ 0.002) ( Table 3) . Prot-SH Oxidation. CSF concentration of prot-SH was about three-fold lower on day 2 in patients randomized to hypothermia than in patients randomized to normothermia (9.45 Ϯ 1.41 vs. 26.59 Ϯ 7.21 nmol/mg protein) (Fig. 3) . Bivariate and multiple regression models revealed a tendency for higher CSF prot-SH levels with hypothermia (p ϭ 0.063 and p ϭ 0.079) ( Table 2 ). In general, there was an inverse relationship between temperature and CSF prot-SH levels at all times after injury, but this was not statistically significant (p ϭ 0.104) ( Table 3) .
F2-Isoprostane. F2-isoprostane levels progressively decreased after the peak on day 1 in patients randomized to normothermia, similar to that previously reported (Fig. 4) . Bivariate and multiple regression models did not reveal a significant effect of hypothermia (Table 2) despite 3.6-fold higher CSF F2-isoprostane levels in patients randomized to normothermia on day 1 after TBI (65.70 Ϯ 24.83 pg/mL) compared with patients randomized to hypothermia (18.23 Ϯ 1.84 pg/ mL) (Fig. 4) . At all times after injury, there was no significant temperature effect on CSF F2-isoprostane levels (p ϭ 0.104) ( Table 3 ).
DISCUSSION
We have previously shown that severe TBI in infants and children is accompanied by marked and progressive compromise of antioxidant defenses and free radical-mediated lipid peroxidation (21) . Here, we present data demonstrating a beneficial effect of hypothermia on oxidative stress in the same setting. Our clinical data are consistent with results in experimental trauma models (13, 22) in that hypothermia attenuates consumption of endogenous antioxidants. In addition, we have shown for the first time that hypothermia tended to decreased protein oxidation. We observed an early peak in F2-isoprostane levels, consistent with our previous study in infants and children (21) , suggesting the possible need for early application of therapies targeting some aspects of oxidative stress after TBI, such as lipid peroxidation.
Possible Mechanisms of Beneficial Effect of Hypothermia on Oxidative Stress after TBI. Mild-moderate hypothermia has been shown to have neuroprotective effects in experimental and clinical brain injury resulting from trauma, cardiac arrest, and ischemia (10, 11, 14, 15, 22, 23 ). The precise mode of neuroprotective action by mild-moderate hypothermia is not known. Most likely, mild-moderate hypothermia exhibits multiple and synergistic effects on brain metabolism; however, it does not indiscriminately slow down all biochemical cascades. There is controversy regarding effects of mildmoderate hypothermia on cerebral energy metabolism likely because of differences in experimental insults and species studied. Mild-moderate hypothermia has been shown to decrease the global cerebral metabolic rate for glucose and oxygen but maintain a slightly better energy level by reducing adenosine triphosphate breakdown (24, 25) . Beneficial effects of mild-moderate hypothermia on energy balance and production of reactive oxygen species in mitochondria have also been reported after experimental ischemia reperfusion injury outside the central nervous system and in retina (26 - 29) . However, classic studies in cerebral ischemia failed to show an effect of mildmoderate hypothermia on energy metabolite levels (30) . Mild-moderate hypothermia reduces the increase in intracellular calcium levels, which is linked to excitotoxicity and oxidative stress, after experimental cerebral ischemia and TBI (31) (32) (33) . The majority of the free radicals that are produced after brain injury are generated by enzymatically catalyzed mechanisms, such as nitric oxide synthase, and by deregulated electron transporters in mitochondria (34 -38) . Therefore, we speculate that beneficial effects of hypothermia on oxidative stress after TBI might be explained by prevention of mitochondrial failure and reduction in excitotoxicity. Moderate hypothermia has been shown to attenuate increases in CSF acetylcholine levels (39) and brain interstitial levels of glutamate and aspartate seen after fluid percussion injury (22) . However, the latter finding was not consistently observed across experimental TBI models (40, 41) . Moderate hypothermia has also been shown to attenuate increases in CSF glutamate levels in adult severe TBI victims (23) .
TBI-induced oxidative stress is importantly linked to inflammatory response. Several components of the local inflammatory response to cerebral contusion are also favorably affected by therapeutic hypothermia in experimental TBI, as evidenced by reductions in neutrophil accumulation (42) (43) (44) , interleukin-1 messenger RNA up-regulation (45, 46) , and inducible nitric oxide synthase activity (47) . Increases in cytokines after severe TBI, however, are not consistently attenuated by therapeutic hypothermia in adults (23, 48, 49) . Similarly, macrophage accumulation as assessed by CSF quinolinic acid levels was not attenuated by moderate hypothermia in adult severe TBI victims (50) .
A beneficial effect of hypothermia on oxidative stress has been shown in experimental studies outside the central nervous system with reduction in lipid peroxidation in ischemic kidney and liver tissue (51, 52) . Antioxidant supplementation with hypothermia had additive protective effects against lipid peroxidation in these experiments. Similarly, our data show that hypothermia only partially restored antioxidant defenses. Given that mild-moderate hypothermia has shown variable or partial beneficial effects (intracranial pressure vs. outcome) in clinical TBI (4, 23, 53, 54) , supplementation with antioxidants may represent a valuable adjunct to hypothermia in the treatment of TBI victims.
Clinical Implications. To date, there have been no studies assessing the effect of therapeutic hypothermia on oxidative stress after TBI in either adults or infants and children. Two large clinical trials in TBI using antioxidants (polyethylene glycol, covalently linked to superoxide dismutase and tirilazad) showed largely negative results (55, 56) . Although these were seminal clinical studies in this area of investigation, they focused exclusively on therapeutic effects on clinical outcome. Neither study assessed whether or not oxidative stress was favorably influenced by the treatment. Furthermore, these two agents appear to have very limited brainpenetrating ability (57) . Our findings suggest that quantification of biomarkers of oxidative stress and antioxidant status of CSF may provide a valuable tool for monitoring treatment effects of antioxidant strategies or other therapies such as hypothermia, anti-excitotoxic, anti-apoptotic, and anti-inflammatory agents after TBI.
We have previously shown gender differences in response to beneficial effects of therapeutic hypothermia on oxidative stress in adults after severe TBI (58, 59) . This study does not show a gender difference in oxidative stress response to hypothermia in infants and children. This may suggest a powerful effect of sex steroids on this specific parameter that would manifest after puberty.
Direct Assessment of Relationship of Biochemical Markers with Temperature.
In this study, we also carried out a separate analysis to directly assess the relationship between markers of oxidative stress and patient temperature at the time of CSF sampling. This second approach demonstrated highly significant preservation effect of hypothermia on antioxidants in CSF-confirming our initial analytical approach. Given that hypothermia took time to induce and that some patients can present with mild hypothermia, this additional statistical approach is, we believe, important to provide a more complete picture of the relationship between markers of oxidative stress and temperature.
Developmental Ramifications. Experimental studies in developmental studies of TBI support the notion that immature brain is particularly vulnerable to oxidative stress because of compromised antioxidant status (60) . Our prior study supported this conclusion and showed profound antioxidant depletion lasting several days after severe TBI (21) . Thus, oxidative stress mechanisms might be an attractive target for therapeutic interventions in developmental central nervous system injury.
Limitations of the Study. Despite the relatively small sample size and considerable variability inpatient age, mechanism of injury, and treatment, statistical significance was achieved in a multivariate analysis between TBI patients randomized to hypothermia vs. normothermia for antioxidant reserve and glutathione. Although this study represents the largest biochemical study of oxidative stress markers in infants and children in a randomized trial of hypothermia after severe TBI, future studies with larger sample size are needed. Despite three-fold lower value of F2-isoprostane in patients randomized to hypothermia vs. normothermia, we were unable to show a significant attenuation of lipid peroxidation by hypothermia. Sample size estimates suggest that 36 patients per group would be needed to appropriately assess for an effect of hypothermia on this parameter accepting a power of 0.8. Similarly, the small number of patients with GCS, three to four in both groups, also limits our ability to assess the effect of hypothermia in most severely injured patients. Although assessment of ventricular CSF provides great promise, it reflects changes across the entire brain and not simply in the injured tissue. It is likely that biochemical alterations seen with hypothermia may, in part, be from healthy brain tissue.
Barbiturates may reduce the overall cerebral metabolism and may, therefore, change the biochemical response. Although there was no statistically significant difference between the groups for barbiturate use (p ϭ 0.48), a greater number of patients in the normothermia group received barbiturates vs. hypothermia group. This suggests that other therapies, such as barbiturates, might be used more frequently for intracranial pressure control in the absence of hypothermia. In additional statistical analysis, barbiturate use did not have consistent effect on the CSF oxidative stress markers assessed in this study. Further studies with a larger sample size, including a comprehensive analysis of biochemical data as it relates to outcome, mortality, mechanism of injury (accidental trauma vs. child abuse), age, gender, other therapies (such as barbiturate use and decompressive craniotomy), are needed. Assessment of the relationship between markers of oxidative stress and associated mechanisms of secondary damage such as apoptosis and excitotoxicity (61, 62) could also be revealing.
Finally, although we cite these limitations, we have also reported, in the same patient population, that hypothermia failed to attenuate the marked increases in CSF cytokine levels after TBI (63) . Taken together, our findings mirror these observations in experimental models of TBI and support a differential effect of mild-moderate hypothermia across injury mechanisms. Future research in this area might improve our understanding of mechanisms of neuroprotection by hypothermia in TBI and enable us augment its beneficial effects by targeted combination therapies.
CONCLUSIONS
Moderate therapeutic hypothermia preserves antioxidant defenses after severe TBI in infants and children. Our data support the concept that CSF represents a valuable tool for monitoring treatment effects on oxidative stress after TBI.
